137 related articles for article (PubMed ID: 3100116)
1. Effects of in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice.
Volk HD; Brocke S; Osawa H; Diamantstein T
Clin Exp Immunol; 1986 Oct; 66(1):126-31. PubMed ID: 3100116
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the local graft-vs.-host reaction in rats by treatment with a monoclonal antibody specific for the interleukin 2 receptor.
Volk HD; Brocke S; Osawa H; Diamantstein T
Eur J Immunol; 1986 Oct; 16(10):1309-12. PubMed ID: 2945730
[TBL] [Abstract][Full Text] [Related]
3. Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18.
Mouzaki A; Volk HD; Osawa H; Diamantstein T
Eur J Immunol; 1987 Mar; 17(3):335-41. PubMed ID: 3106058
[TBL] [Abstract][Full Text] [Related]
4. Anti-receptor anti-MHC cytotoxic T lymphocytes: their role in the resistance to graft vs host reaction.
Kosmatopoulos K; Algara DS; Orbach-Arbouys S
J Immunol; 1987 Feb; 138(4):1038-41. PubMed ID: 3492538
[TBL] [Abstract][Full Text] [Related]
5. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
Moser M; Sharrow SO; Shearer GM
J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.
Volk HD; Josimovic-Alasevic O; Gross M; Diamantstein T
Clin Exp Immunol; 1989 Apr; 76(1):121-5. PubMed ID: 2786777
[TBL] [Abstract][Full Text] [Related]
7. A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL 2 receptor functions: a putative anti-IL 2 receptor antibody.
Osawa H; Diamantstein T
J Immunol; 1984 May; 132(5):2445-50. PubMed ID: 6425405
[TBL] [Abstract][Full Text] [Related]
8. Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.
Diamantstein T; Volk HD; Tilney NL; Kupiec-Weglinski J
Immunobiology; 1986 Sep; 172(3-5):391-9. PubMed ID: 3100433
[TBL] [Abstract][Full Text] [Related]
9. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
10. Alloreactive lymphocytes from T cell receptor (beta-chain) transgenic mice do not mediate a graft-versus-host reaction.
Rimm IJ; Ghayur T; Gasser DL; Rosenkrantz K; Burakoff SJ; Seidman JG; Ferrara JL
J Immunol; 1991 Feb; 146(4):1130-3. PubMed ID: 1825104
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 receptor dysfunction in mice undergoing a graft-vs-host reaction.
Joseph LJ; Iwasaki T; Malek TR; Shearer GM
J Immunol; 1985 Sep; 135(3):1846-50. PubMed ID: 3926888
[TBL] [Abstract][Full Text] [Related]
12. Modulation of F1 cytotoxic potentials by GvHR: role and mode of action of non-MHC genes that determine the hybrid resistance to GvHR-associated suppression of F1 cytotoxic potential.
Ishikawa H; Kubota E; Saito K
J Immunol; 1984 May; 132(5):2218-25. PubMed ID: 6232314
[TBL] [Abstract][Full Text] [Related]
13. Preferential activation of Th2 cells in chronic graft-versus-host reaction.
De Wit D; Van Mechelen M; Zanin C; Doutrelepont JM; Velu T; Gérard C; Abramowicz D; Scheerlinck JP; De Baetselier P; Urbain J
J Immunol; 1993 Jan; 150(2):361-6. PubMed ID: 8419469
[TBL] [Abstract][Full Text] [Related]
14. The murine IL 2 receptor. III. Cellular requirements for the induction of IL 2 receptor expression on T cell subpopulations.
Malek TR; Schmidt JA; Shevach EM
J Immunol; 1985 Apr; 134(4):2405-13. PubMed ID: 3919092
[TBL] [Abstract][Full Text] [Related]
15. Modulation of F1 cytotoxic potentials by GvHR. Host- and donor-derived cytotoxic lymphocytes arise in the unirradiated F1 host spleens under the condition of GvHR-associated immunosuppression.
Kubota E; Ishikawa H; Saito K
J Immunol; 1983 Sep; 131(3):1142-8. PubMed ID: 6604089
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of lymphoid tissues under the influence of a subclinical level of graft versus host reaction induced by bone marrow T cells or splenic T cell subsets.
Hirano M; Arase H; Arase-Fukushi N; Ogasawara K; Iwabuchi K; Miyazaki T; Good RA; Onoé K
Cell Immunol; 1993 Oct; 151(1):118-32. PubMed ID: 8402923
[TBL] [Abstract][Full Text] [Related]
17. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms.
Guy-Grand D; Vassalli P
J Clin Invest; 1986 May; 77(5):1584-95. PubMed ID: 3486193
[TBL] [Abstract][Full Text] [Related]
18. The rat mixed lymphocyte reaction: roles of a dendritic cell in intestinal lymph and T-cell subsets defined by monoclonal antibodies.
Mason DW; Pugh CW; Webb M
Immunology; 1981 Sep; 44(1):75-87. PubMed ID: 6456222
[TBL] [Abstract][Full Text] [Related]
19. Evidence for two distinct mechanisms in acute fatal graft-versus-host reaction across minor histocompatibility barriers.
OKunewick JP; Buffo MJ; Kociban DL
Exp Hematol; 1987 May; 15(4):365-72. PubMed ID: 3494625
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-host reaction-induced immune modulation. I. Donor-recipient genetic disparity and the differential expression of Lyt-2, L3T4, and Ly-6 during acute reactions in the host thymus.
Levy RB; Cotterell AH; Jones M; Malek TR
J Immunol; 1988 Mar; 140(6):1717-25. PubMed ID: 3257983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
